International Center of Excellence for oncology biomarker and inflammation translational services created
San Diego, Calif – May 9, 2019 – Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular, and metabolic disease research, today announced the opening of a new facility in San Diego, CA. The new site will become CrownBio’s International Center of Excellence for oncology biomarker and inflammation services.
CrownBio’s presence in San Diego, CA has grown from 17 employees in 2015 to more than 70 today, with additional hiring expected. The custom-designed 32,000 sq. ft. facility provides the additional capacity required to support the growth CrownBio forecasts in its oncology biomarker and inflammation service portfolios. As part of the expansion, significant investment was also made in the latest flow cytometry, radiation and imaging technologies.
In the newly created Center of Excellence, CrownBio will enhance its current translational platforms by expanding its existing service portfolio, as well as develop an additional new suite of oncology and inflammation platforms.
The fully-operational facility is designed to ensure a streamlined workflow to optimize study efficiency. Featuring a state-of-the-art ABSL-2 vivarium and laboratory housing an infectious suite and quarantine facilities, the new site hosts significant laboratory space dedicated to storing cryo-preserved cells and tissue, including the world’s largest commercially available collection of patient-derived xenograft (PDX) models.
“The establishment of our International Center of Excellence in San Diego is both an indicator of our continued growth and a commitment to our global and domestic customers,” said CrownBio COO Yangzhou Wang. “The expansion allows us to add to our talented and diverse workforce, which will in turn support the development of novel cancer therapies globally.”
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Copy link
https://news.jsrlifesciences.com/212684-crown-bioscience-announces-san-diego-ca-site-expansionRelated topics
Related news
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...
Crown Bioscience Enables HanX Biopharmaceutical to Progress HX009 to Clinical Trials
Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, announced today that it has completed its acquisition of the IndivuServ business unit of Indivumed Gmb...